Project Grant R01DA065104
- Federal Grant Award Summary Albert Einstein College of Medicine received a $756,000 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a pilot study improving PrEP (pre-exposure prophylaxis) engagement among hospitalized people who use substances (PWUS). The award, effective March 15, 2026 through February 28, 2029, will support formative research and implementation science activities addressing barriers to HIV...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $659,242 Project Grant (CFDA 93.242 - Mental Health Research Grants) to Public Health Foundation Enterprises, Inc. (doing business as Heluna Health) on March 5, 2026, with a completion date of November 30, 2030. The PREP BLUEPRINT project will develop and evaluate a comprehensive blueprint designed to assist clinics in scaling up Pre-Exposure Prophylaxis (PrEP) services and expanding access to all available PrEP...
- Federal Grant Award Summary Rhode Island Hospital has received a $573,320 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), effective August 1, 2025 through April 30, 2028. The award supports the development and preliminary testing of a nurse-led HIV pre-exposure prophylaxis (PrEP) intervention designed for incarcerated individuals. The primary deliverables include finalized intervention materials, clinical protocols, and an...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded University of California, San Diego $1,573,958 under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning August 1, 2025, through April 30, 2030. This Project Grant supports a hybrid Type I implementation trial titled "Breaking Barriers: Innovating HIV Elimination with Social Network Strategies and Routine Substance Use Screening." The study delivers two primary interventions: (1)...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $188,995.00 to the University of Pittsburgh under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 15, 2025, for the "Prescribe to Prevent HIV" (P2PH) trial, with a completion date of July 31, 2028. This project grant supports implementation research aimed at addressing the urgent health crisis of severe injection-related infections (SIRI), including HIV, among the estimated...
- Federal Grant Award Summary This $554,922 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a three-year research initiative (September 1, 2025 – August 31, 2028) examining the efficacy and impact of Project HOPE, a health vending machine program designed to improve HIV prevention outcomes among people who use drugs (PWUD). The research will employ a longitudinal mixed-methods approach to evaluate whether...
- Federal Grant Award Summary: HIP-PHARM Project Wake Forest University Health Sciences received a $1.55 million Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective July 1, 2025, through March 31, 2030. The HIP-PHARM (Integrated HIV and Overdose Prevention in Pharmacies) project delivers a comprehensive research assessment of HIV pre-exposure prophylaxis (PrEP) and overdose prevention service...
- Federal Grant Award Summary The University of Miami received a $677,248 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test the Comprehensive Telehealth Concierge (C-THR) model. The grant, awarded February 15, 2026, with a completion date of December 31, 2030, funds a randomized controlled trial designed to improve HIV Pre-Exposure Prophylaxis (PrEP) initiation and retention among individuals with...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded J. David Gladstone Institutes a $1,343,271 Project Grant (CFDA 93.279, Drug Use and Addiction Research Programs) effective May 15, 2025, through March 31, 2030, to develop targeted small molecule recruitment strategies for suppressing the HIV transcriptionally active reservoir in individuals with substance use disorder (SUD). The research addresses a critical gap in antiretroviral therapy (ART), which fails to target latent...
- Federal Project Grant Award Summary New York University School of Medicine received a $771,043 Project Grant awarded on March 15, 2026, from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a hybrid Type II implementation-effectiveness trial designed to improve HIV prevention and substance use treatment outcomes for people who inject drugs. The primary deliverable is a social network-based peer change agent intervention called...
Public Health Foundation Enterprises, Inc. (doing business as Heluna Health) received a $588,669 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) on April 15, 2026, with an ultimate completion date of January 31, 2031. The award funds the Street Prep intervention, which delivers evidence-based HIV prevention services directly to people who use drugs and experience homelessness in San Francisco. The project will recruit 150 high-risk participants through respondent-driven sampling leveraging an existing cohort study and social networks within the drug-using population, then randomize them to either standard clinic linkages or the Street Prep intervention arm. The Street Prep intervention provides comprehensive, low-barrier services including access to a mobile health clinic, tailored navigation addressing both HIV prevention and substance use needs, and transportation to low-barrier drop-in clinics for ongoing healthcare. The project will employ a Type 2 hybrid effectiveness-implementation randomized trial design to measure the intervention's impact on pre-exposure prophylaxis (PrEP) uptake and persistence among a population experiencing significant structural barriers to HIV prevention services. This research addresses a critical public health gap, as new HIV diagnoses among people who inject drugs in San Francisco increased 34 percent from 2019 to 2021, while PrEP utilization in this population remains extremely low at 1.2 percent annually.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $588.7k | 4/13/26 |